Sichere dir deine Prämie beim Kostensieger

Unser Broker finanzen.net ZERO ist mehrfacher Kostensieger der Stiftung Warentest (12/2025) - und schenkt dir zum Start 50 € Prämie, 1 Lufthansa-Aktie und 2 MSCI World-Anteile. Starte jetzt mit Code 'BONUS2026'!

Es gelten die Teilnahmebedingungen.

Nicht mehr anzeigen

ImmunityBio Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

6,15 EUR -0,36 EUR -5,53 %

18:18:06

STU

6,21 EUR -0,32 EUR -4,90 %

18:23:32

HAML

ImmunityBio jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.6,62 Mrd. EUR

Div. Rendite0,00%

WKNA2QQ2E

ISINUS45256X1037

SymbolIBRX

ImmunityBio Aktien News

Sortieren:Datum Meistgelesen

21.11.24PR NewswireImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

19.11.24PR NewswireImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

11.10.24PR NewswireIMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

WerbungImmunityBio-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

28.08.23PR NewswireSHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. (IBRX) Shareholders

18.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

15.08.23PR NewswireIBRX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. Shareholders

14.08.23PR NewswireROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX

14.08.23PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating ImmunityBio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

10.08.23PR NewswireIBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

04.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

31.07.23PR NewswireIBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit

28.07.23PR NewswireIBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023

27.07.23PR NewswireIBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

25.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

21.07.23PR NewswireIBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023

12.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

05.07.23PR NewswireCalling All ImmunityBio, Inc. (IBRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC Today!

19.05.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

ImmunityBio News

ImmunityBio News: auf dieser Seite finden Sie alle ImmunityBio News und Nachrichten zur ImmunityBio Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch ImmunityBio News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um ImmunityBio News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.